Contribute Try STAT+ Today

CHICAGO — Moderna Therapeutics (MRNA) has already raised billions of dollars, pulled off the largest IPO in biotech history, and now carries a market valuation of more than $7 billion. Saturday, the messenger RNA “startup” made its debut at the American Society of Clinical Oncology annual meeting, showcasing for the first time some early data on a personalized cancer vaccine.

The vaccine, called mRNA-4157, was administered alone and in combination with Merck’s checkpoint inhibitor Keytruda without any serious side effects. The patients were injected with the customized vaccine after their solid tumors had been removed via surgery. Immune responses were detected and most remain in remission, suggesting the vaccine was helping the patient’s body recognize and attack the unique proteins found on tumor cells.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.